

Anna Orlova

List of Publications by Citations

Source: <https://exaly.com/author-pdf/536085/anna-orlova-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

209
papers

6,448
citations

44
h-index

69
g-index

221
ext. papers

7,222
ext. citations

5.7
avg, IF

5.76
L-index

#	Paper	IF	Citations
209	Tumor imaging using a picomolar affinity HER2 binding affibody molecule. <i>Cancer Research</i> , 2006 , 66, 4339-48	10.1	405
208	Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 892-7	8.9	233
207	Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. <i>Cancer Research</i> , 2007 , 67, 2773-82	10.1	179
206	Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. <i>Cancer Research</i> , 2007 , 67, 2178-86	10.1	161
205	Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT. <i>Theranostics</i> , 2016 , 6, 262-71	12.1	146
204	On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 417-25	8.9	124
203	Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. <i>Journal of Molecular Biology</i> , 2008 , 376, 1388-402	6.5	118
202	Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 555-68	5.4	106
201	Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008 , 23, 435-42	3.9	99
200	Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 613-22	8.8	97
199	Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 274-83	8.9	91
198	Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 781-9	8.9	90
197	Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. <i>Lancet Oncology, The</i> , 2010 , 11, 992-1000	21.7	88
196	(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. <i>Bioconjugate Chemistry</i> , 2007 , 18, 1956-64	6.3	88
195	Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. <i>Bioconjugate Chemistry</i> , 2008 , 19, 235-43	6.3	76
194	Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007 , 34, 722-733	8.8	76
193	Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 1131-8	8.9	73

192	111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 846-53	8.9	72
191	Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 885-891	8.9	71
190	A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 1356-67	8.8	71
189	Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 961-8	8.9	69
188	99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007 , 34, 1843-53	8.8	69
187	Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 867-71	8.9	69
186	Pharmacologic inhibition of STAT5 in acute myeloid leukemia. <i>Leukemia</i> , 2018 , 32, 1135-1146	10.7	68
185	Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 461-9	8.9	68
184	HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with $^{99m}\text{Tc}(\text{CO})\text{I}^+$, and shows improved biodistribution with reduced hepatic radioactivity accumulation. <i>Bioconjugate Chemistry</i> , 2010 , 21, 2013-22	6.3	63
183	Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 512-9	8.9	63
182	Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 953-60	8.9	61
181	Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets. <i>Current Medicinal Chemistry</i> , 2010 , 17, 2636-55	4.3	59
180	Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008 , 35, 2245-55	8.8	58
179	Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006 , 33, 631-8	8.8	58
178	Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging. <i>Bioconjugate Chemistry</i> , 2013 , 24, 1144-53	6.3	56
177	Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. <i>Cancer Immunology Research</i> , 2014 , 2, 80-90	12.5	55
176	Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. <i>Drug Discovery Today</i> , 2012 , 17, 1224-32	8.8	55
175	Affibody-mediated PET imaging of HER3 expression in malignant tumours. <i>Scientific Reports</i> , 2015 , 5, 15226	4.9	51

174	In vivo evaluation of cysteine-based chelators for attachment of ^{99m} Tc to tumor-targeting Affibody molecules. <i>Bioconjugate Chemistry</i> , 2007 , 18, 549-58	6.3	51
173	Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. <i>PLoS ONE</i> , 2013 , 8, e62791	3.7	51
172	Update: affibody molecules for molecular imaging and therapy for cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007 , 22, 573-84	3.9	50
171	ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers. <i>Cancer Research</i> , 2015 , 75, 4364-71	10.1	47
170	HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(^{99m} Tc(CO) ₃](+)-labeled affibody molecules. <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 4966-74	8.3	47
169	Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009 , 36, 692-701	8.8	47
168	Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. <i>Bioconjugate Chemistry</i> , 2005 , 16, 1547-55	6.3	47
167	The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a ⁶⁸ Ga-labeled NOTA-conjugated antagonistic analog of bombesin. <i>Molecules</i> , 2014 , 19, 10455-72	4.8	46
166	Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors. <i>Theranostics</i> , 2016 , 6, 93-103	12.1	46
165	Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 431-6	8.9	44
164	Influence of macrocyclic chelators on the targeting properties of (⁶⁸ Ga)-labeled synthetic affibody molecules: comparison with (¹¹¹ In)-labeled counterparts. <i>PLoS ONE</i> , 2013 , 8, e70028	3.7	44
163	Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (^{99m} Tc), (¹¹¹ In), and (¹²⁵ I). <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 3817-26	8.3	43
162	Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011 , 38, 531-9	8.8	42
161	Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule ¹¹¹ In-DOTA-ZIGF1R:4551. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 90-7	8.9	41
160	Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of ^{99m} Tc-labeled anti-HER2 Affibody molecules. <i>Bioconjugate Chemistry</i> , 2008 , 19, 2568-76	6.3	41
159	PET imaging of epidermal growth factor receptor expression in tumours using ⁸⁹ Zr-labelled ZEGFR:2377 affibody molecules. <i>International Journal of Oncology</i> , 2016 , 48, 1325-32	4.4	41
158	Imaging of platelet-derived growth factor receptor expression in glioblastoma xenografts using affibody molecule ¹¹¹ In-DOTA-Z09591. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 294-300	8.9	40
157	The effect of macrocyclic chelators on the targeting properties of the ⁶⁸ Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26. <i>Nuclear Medicine and Biology</i> , 2015 , 42, 446-454	2.1	40

156	In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging. <i>PLoS ONE</i> , 2013 , 8, e81932	3.7	40
155	Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009 , 36, 1864-73	8.8	40
154	Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 1450-9	8.8	38
153	Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ^{67}Ga and ^{111}In via maleimido derivatives of DOTA and NODAGA. <i>Bioconjugate Chemistry</i> , 2013 , 24, 1102-9	6.3	37
152	(186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 260-9	8.8	37
151	Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides. <i>Current Medicinal Chemistry</i> , 2003 , 10, 2447-60	4.3	37
150	Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with ^{111}In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 481-92	8.8	35
149	Gallium-68-labeled affibody molecule for PET imaging of PDGFR α expression in vivo. <i>Molecular Pharmaceutics</i> , 2014 , 11, 3957-64	5.6	34
148	Cellular processing of (125)I- and (111)in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells. <i>Nuclear Medicine and Biology</i> , 2000 , 27, 827-35	2.1	34
147	Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1092-1098	8.9	33
146	Affibody Molecules as Targeting Vectors for PET Imaging. <i>Cancers</i> , 2020 , 12,	6.6	32
145	Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins. <i>Bioconjugate Chemistry</i> , 2016 , 27, 716-26	6.3	31
144	[$^{99m}\text{Tc}(\text{CO})_3$]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 439-49	8.8	31
143	Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-Z HER2:2395(-Cys) affibody molecule for targeting of HER2-expressing tumors. <i>Molecular Imaging and Biology</i> , 2010 , 12, 54-62	3.8	31
142	Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules. <i>Bioconjugate Chemistry</i> , 2012 , 23, 1661-70	6.3	30
141	Closo-dodecaborate(2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution. <i>Bioconjugate Chemistry</i> , 1999 , 10, 338-45	6.3	29
140	Direct Targeting Options for STAT3 and STAT5 in Cancer. <i>Cancers</i> , 2019 , 11,	6.6	29
139	Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors. <i>Journal of Controlled Release</i> , 2018 , 288, 84-95	11.7	29

138	Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 93-99	8.9	28
137	Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules. <i>Molecular Pharmaceutics</i> , 2016 , 13, 1668-78	5.6	28
136	In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors. <i>Cancer Biotherapy and Radiopharmaceutics</i> , 2013 , 28, 187-95	3.9	28
135	The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule. <i>Scientific Reports</i> , 2017 , 7, 5961	4.9	27
134	Methods for radiolabelling of monoclonal antibodies. <i>Methods in Molecular Biology</i> , 2014 , 1060, 309-30	1.4	26
133	Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on ¹¹¹ In- and ¹²⁵ I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody. <i>Nuclear Medicine and Biology</i> , 2017 , 38, 1000-1003	2.1	26
132	The influence of Bz-DOTA and CHX-AR ² DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (^{114m} In)-mediated targeting therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009 , 36, 1460-8	8.8	26
131	Comparative evaluation of ¹¹¹ In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors. <i>Oncology Reports</i> , 2015 , 34, 1042-8	3.5	25
130	Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules. <i>Bioconjugate Chemistry</i> , 2011 , 22, 894-902	6.3	25
129	Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects. <i>International Journal of Oncology</i> , 2010 , 36, 757-63	4.4	25
128	Phase I Study of Tc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 493-499	8.9	25
127	Labelling chemistry and characterization of [⁹⁰ Y/ ¹⁷⁷ Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. <i>International Journal of Molecular Medicine</i> , 2007 , 19, 285-91	4.4	25
126	Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX. <i>Molecular Pharmaceutics</i> , 2016 , 13, 3676-3687	5.6	24
125	Comparative Evaluation of Radioiodine and Technetium-Labeled DARPIn 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors. <i>Contrast Media and Molecular Imaging</i> , 2018 , 2018, 6930425	3.2	24
124	Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (¹⁸ F)-4-fluorobenzaldehyde. <i>Bioconjugate Chemistry</i> , 2014 , 25, 82-92	6.3	24
123	Cyclic versus Noncyclic Chelating Scaffold for Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. <i>Molecular Pharmaceutics</i> , 2018 , 15, 175-185	5.6	24
122	Optimal composition and position of histidine-containing tags improves biodistribution of Tc-labeled DARPIn G3. <i>Scientific Reports</i> , 2019 , 9, 9405	4.9	23
121	Evaluation of a maleimido derivative of CHX-AR ² DTPA for site-specific labeling of affibody molecules. <i>Bioconjugate Chemistry</i> , 2008 , 19, 1579-87	6.3	23

120	Combined effect of gefitinib (RressaRZD1839) and targeted radiotherapy with 211At-EGF. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003 , 30, 1348-56	8.8	23
119	Comparative Evaluation of Two DARPIn Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties. <i>Molecular Pharmaceutics</i> , 2019 , 16, 995-1008	5.6	23
118	Optimized indirect (76)Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate for radioimmuno PET. <i>Nuclear Medicine and Biology</i> , 2000 , 27, 837-43	2.1	22
117	High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26. <i>Contrast Media and Molecular Imaging</i> , 2017 , 2017, 6873684	3.2	21
116	Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin. <i>International Journal of Oncology</i> , 2016 , 49, 1185-94	4.4	21
115	Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator. <i>International Journal of Oncology</i> , 2016 , 49, 2285-2293	4.4	21
114	Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [(111)In]-labeled CHX-A?DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines. <i>Experimental and Therapeutic Medicine</i> , 2011 , 2, 523-528	2.1	21
113	Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET. <i>Nuclear Medicine and Biology</i> , 2005 , 32, 613-22	2.1	21
112	Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. <i>International Journal of Oncology</i> , 2016 , 48, 2124-34	4.4	20
111	188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1842-8	8.9	20
110	Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors. <i>International Journal of Molecular Medicine</i> , 2007 , 20, 397-404	4.4	20
109	Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression. <i>Amino Acids</i> , 2015 , 47, 303-15	3.5	19
108	Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020 , 5, 16	5.8	19
107	Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model. <i>Theranostics</i> , 2018 , 8, 4462-4476	12.1	19
106	Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus. <i>Tumor Biology</i> , 2012 , 33, 641-51	2.9	17
105	Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line. <i>International Journal of Oncology</i> , 2012 , 40, 1677-82	4.4	17
104	In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. <i>Scientific Reports</i> , 2017 , 7, 43118	4.9	16
103	Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009 , 19, 3912-4	2.9	16

102	Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of Ga-Labeled Tracers. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	15
101	Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe. <i>Scientific Reports</i> , 2018 , 8, 2998	4.9	15
100	Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab. <i>Molecular Pharmaceutics</i> , 2018 , 15, 3394-3403	5.6	15
99	[(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent. <i>Cancer Biotherapy and Radiopharmaceutics</i> , 2003 , 18, 643-54	3.9	15
98	Closo-dodecaborate (2-) anion as a potential prosthetic group for attachment of astatine to proteins. Aspects of the labelling chemistry with chloramine-T. <i>Journal of Labelled Compounds and Radiopharmaceutics</i> , 2000 , 43, 251-260	1.9	15
97	Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019 , 134, 37-48	5.7	15
96	Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist Lu-DOTAGA-PEG -RM26. <i>International Journal of Cancer</i> , 2019 , 145, 3347-3358	7.5	14
95	Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules. <i>Amino Acids</i> , 2012 , 42, 1975-85	3.5	14
94	Synthesis and chemoselective intramolecular crosslinking of a HER2-binding affibody. <i>Biopolymers</i> , 2009 , 92, 116-23	2.2	14
93	Histidine-rich glycoprotein uptake and turnover is mediated by mononuclear phagocytes. <i>PLoS ONE</i> , 2014 , 9, e107483	3.7	14
92	Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs. <i>Cells</i> , 2018 , 7,	7.9	14
91	Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer. <i>Cancers</i> , 2019 , 11,	6.6	13
90	Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111. <i>Scientific Reports</i> , 2019 , 9, 655	4.9	13
89	Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting. <i>Biomaterials</i> , 2019 , 203, 73-85	15.6	13
88	Synthesis of C-labeled Sulfonyl Carbamates through a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols, and [C]CO. <i>ChemistryOpen</i> , 2016 , 5, 566-573	2.3	13
87	Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re. <i>European Journal of Medicinal Chemistry</i> , 2014 , 87, 519-28	6.8	13
86	Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m. <i>Scientific Reports</i> , 2017 , 7, 14780	4.9	13
85	Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution. <i>International Journal of Oncology</i> , 2014 , 44, 1998-2008	4.4	13

84	Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine. <i>Current Pharmaceutical Design</i> , 2014 , 20, 2275-92	3.3	13
83	Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [¹¹¹ In]DTPA-hEGF and [¹¹¹ In]Bz-DTPA-hEGF in Normal Mice. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004 , 19, 491-501	3.9	13
82	Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1. <i>International Journal of Biological Macromolecules</i> , 2020 , 145, 216-225	7.9	13
81	Preclinical Evaluation of [⁶⁷ Zn]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors. <i>Cells</i> , 2018 , 7,	7.9	13
80	Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	12
79	Selection of the optimal macrocyclic chelators for labeling with In and Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019 , 140, 109-120	5.7	12
78	Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6. <i>Bioconjugate Chemistry</i> , 2016 , 27, 2678-2688	6.3	12
77	Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with In and Ga. <i>Molecular Pharmaceutics</i> , 2018 , 15, 2674-2683	5.6	12
76	Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging. <i>Nuclear Medicine and Biology</i> , 2013 , 40, 378-86	2.1	12
75	Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with ¹¹¹ In using a maleimido derivative of NODAGA. <i>Nuclear Medicine and Biology</i> , 2012 , 39, 518-29	2.1	12
74	Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2002 , 17, 385-96	3.9	12
73	Influence of composition of cysteine-containing peptide-based chelators on biodistribution of Tc-labeled anti-EGFR affibody molecules. <i>Amino Acids</i> , 2018 , 50, 981-994	3.5	11
72	Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer. <i>Pharmaceutics</i> , 2019 , 11,	6.4	11
71	Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of ⁶⁸ Ga- compared to ¹¹¹ In-labeled conjugates. <i>Molecular Imaging</i> , 2014 , 13,	3.7	11
70	Imaging agents for in vivo molecular profiling of disseminated prostate cancer--targeting EGFR receptors in prostate cancer: comparison of cellular processing of [¹¹¹ In]-labeled affibody molecule Z(EGFR:2377) and cetuximab. <i>International Journal of Oncology</i> , 2011 , 38, 1137-43	4.4	11
69	Comparative biodistribution of potential anti-glioblastoma conjugates [¹¹¹ In]DTPA-hEGF and [¹¹¹ In]Bz-DTPA-hEGF in normal mice. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004 , 19, 491-501	3.9	11
68	Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with Cu Using NOTA and NODAGA. <i>Contrast Media and Molecular Imaging</i> , 2017 , 2017, 8565802	3.2	10
67	Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression. <i>International Journal of Oncology</i> , 2017 , 51, 1765-1774	4.4	10

66	Molecular design of radiocopper-labelled Affibody molecules. <i>Scientific Reports</i> , 2018 , 8, 6542	4.9	10
65	Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity. <i>ChemistryOpen</i> , 2015 , 4, 174-82	2.3	10
64	Preparation and in vitro evaluation of ¹¹¹ In-CHX-A"-DTPA-labeled anti-VEGF monoclonal antibody bevacizumab. <i>Human Antibodies</i> , 2010 , 19, 107-11	1.3	10
63	[¹⁷⁷ Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004 , 19, 195-204	3.9	10
62	Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26. <i>Scientific Reports</i> , 2019 , 9, 17086	4.9	10
61	Increase in negative charge of Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules. <i>Scientific Reports</i> , 2019 , 9, 17710	4.9	10
60	[^{99m} Tc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation. <i>Oncology Reports</i> , 2005 , 13, 1169-75	3.5	10
59	Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2. <i>International Journal of Oncology</i> , 2019 , 54, 1209-1220	4.4	9
58	Direct comparison of ¹¹¹ In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 693-702	8.8	9
57	In vitro characterization of ²¹¹ At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2005 , 20, 514-23	3.9	9
56	Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts. <i>Scientific Reports</i> , 2019 , 9, 14907	4.9	9
55	Phase I trial of Tc-(HE)-G3, a DARPin-based probe for imaging of HER2 expression in breast cancer. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.9	9
54	Radio-iodination of monoclonal antibody using potassium [¹²⁵ I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (iodo-DABI). <i>Anticancer Research</i> , 2006 , 26, 1217-23	2.3	9
53	Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
52	Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
51	Detecting ligand interactions with G protein-coupled receptors in real-time on living cells. <i>Biochemical and Biophysical Research Communications</i> , 2013 , 441, 820-4	3.4	8
50	Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (¹¹¹)In-labeled conjugate. <i>Nuclear Medicine and Biology</i> , 2011 , 38, 697-706	2.1	8
49	Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy. <i>Scientific Reports</i> , 2018 , 8, 9643	4.9	8

48	Potent and specific fusion toxins consisting of a HER2-binding, ABD-derived affinity protein, fused to truncated versions of Pseudomonas exotoxinA. <i>International Journal of Oncology</i> , 2019 , 55, 309-319	4.4	7
47	Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. <i>Cancers</i> , 2020 , 13,	6.6	7
46	Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model. <i>Pharmaceutics</i> , 2020 , 12,	6.4	7
45	PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	7
44	Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells. <i>Anticancer Research</i> , 2004 , 24, 4035-41	2.3	7
43	Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand. <i>International Journal of Molecular Medicine</i> , 2007 , 19, 485-93	4.4	7
42	Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake. <i>Scientific Reports</i> , 2019 , 9, 6779	4.9	6
41	Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates. <i>Cancers</i> , 2019 , 11,	6.6	6
40	Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPIn Ec1. <i>Molecules</i> , 2020 , 25,	4.8	6
39	Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting. <i>Scientific Reports</i> , 2020 , 10, 20777	4.9	6
38	Comparative Evaluation of Novel Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting. <i>Cancers</i> , 2021 , 13,	6.6	6
37	The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer. <i>Seminars in Cancer Biology</i> , 2021 , 72, 185-197	12.7	6
36	Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients. <i>Oncology Letters</i> , 2015 , 9, 950-954	2.6	5
35	Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart. <i>Pharmaceutics</i> , 2019 , 11,	6.4	5
34	In vitro modeling of HER2-targeting therapy in disseminated prostate cancer. <i>International Journal of Oncology</i> , 2014 , 45, 2153-8	4.4	5
33	Targeting of a head and neck squamous cell carcinoma xenograft model using the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. <i>Acta Oto-Laryngologica</i> , 2004 , 124, 1078-85	1.6	5
32	Copper-mediated isotopic exchange between [125I]iodide and bis(triethylammonium) undecahydro-12-iodo-closo-dodecaborate in aqueous media. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2004 , 260, 295-299	1.5	5
31	Synthesis and Radioiodination of Some 9-Aminoacridine Derivatives. <i>European Journal of Organic Chemistry</i> , 2004 , 2004, 3719-3725	3.2	5

30	Feasibility of isotopic exchange in the system [125I] iodide - undecahydro-iodo-closo-dodecaborate(2-) anion. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2003 , 256, 67-71	1.5	5
29	Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer - Influence of Labeling Chemistry on Targeting Properties. <i>Current Medicinal Chemistry</i> , 2020 , 27, 7090-7111	4.3	5
28	A method of drug delivery to tumors based on rapidly biodegradable drug-loaded containers. <i>Applied Materials Today</i> , 2021 , 25, 101199	6.6	5
27	Comparing the measured affinity of 111In-labeled ligands for cellular receptors by monitoring gamma, beta, or X-ray radiation with three different LigandTracer \square devices. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2015 , 304, 823-828	1.5	4
26	Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model. <i>Pharmaceutics</i> , 2020 , 12,	6.4	4
25	Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
24	Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use. <i>Bulletin of Siberian Medicine</i> , 2021 , 20, 23-30	0.4	4
23	Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [Ga]Ga-NOTA-PEG-RM26. <i>Scientific Reports</i> , 2021 , 11, 3631	4.9	4
22	The Use of a Non-Conventional Long-Lived Gallium Radioisotope Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule. <i>Pharmaceutics</i> , 2021 , 13,	6.4	4
21	Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model. <i>Cancers</i> , 2021 , 13,	6.6	4
20	Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. <i>International Journal of Molecular Medicine</i> , 2007 , 19, 285	4.4	3
19	Optimization of Iodination of [125I]-N-Succinimidyl-Para-Iodobenzoate Using Chloramine-T for Labeling of Proteins. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2000 , 246, 207-213	1.5	3
18	Preclinical Evaluation of Tc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
17	Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPIn Ec1. <i>Cancers</i> , 2021 , 13,	6.6	3
16	Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle. <i>Biomaterials</i> , 2021 , 266, 120381	15.6	3
15	Affibody-mediated imaging of EGFR expression in prostate cancer using radiocobalt-labeled DOTA-ZEGFR:2377. <i>Oncology Reports</i> , 2019 , 41, 534-542	3.5	3
14	HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution. <i>Pharmaceutics</i> , 2020 , 12,	6.4	2
13	Radioiodination of ammonio-closo-monocarborane, 1-H3N-1-CB11H11. Aspects of labelling chemistry in aqueous solution using Chloramine-T. <i>Radiochimica Acta</i> , 2004 , 92, 311-315	1.9	2

12	Preparation of [76Br] 5-bromo-2-thiouracil, a positron-emitting melanoma localizing agent. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2002 , 251, 409-412	1.5	2
11	The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy. <i>Pharmaceutics</i> , 2021 , 13,	6.4	2
10	Increasing thermal stability and improving biodistribution of VEGFR2-binding affibody molecules by a combination of in silico and directed evolution approaches. <i>Scientific Reports</i> , 2020 , 10, 18148	4.9	2
9	Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer. <i>Molecules</i> , 2020 , 25,	4.8	2
8	Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution. <i>Pharmaceutics</i> , 2021 , 13,	6.4	2
7	Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody Molecules Lu-ABY-271 and Lu-ABY-027: Impact of DOTA Position on ABD Domain. <i>Pharmaceutics</i> , 2021 , 13,	6.4	2
6	Preclinical Evaluation of Tc-Labeled GRPR Antagonists maSSS/SES-PEG-RM26 for Imaging of Prostate Cancer. <i>Pharmaceutics</i> , 2021 , 13,	6.4	2
5	HER3 PET Imaging: Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to Zr-Labeled Antibody and Antibody-Fragment-Based Tracers. <i>Cancers</i> , 2021 , 13,	6.6	2
4	Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. <i>Pharmaceutics</i> , 2021 , 13,	6.4	1
3	Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands. <i>Pharmaceutics</i> , 2022 , 14, 1098	6.4	0
2	Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules. <i>Biomedicines</i> , 2022 , 10, 1293	4.8	0
1	An aminoacridine derivative for radionuclide therapy: DNA binding properties studied in a novel cell-free in vitro assay 2005 , 27, 1355		